Oliver Leatham is a Partner in Clarivate’s Commercial Strategy Consulting team and Head of RWE Consulting.
Oliver has 25 years experience working in Market Access and Real World Data (RWD). Oliver previously headed the Consulting Practice in Certara and PAREXEL working across Market Access, HEOR, and RWE.
Our Team provides expert advice in RWE Strategy and evidence gap assessment, to support HTA submissions in Oncology, Immunotherapy and Rare Disease. This includes: Protocol Design, Landscape Assessment/Epidemiology, Retrospective/Prospective Studies, Chart Reviews and Single-Arm Trial Designs. To supplement our data capabilities, we have developed significant expertise in predictive modelling and Machine Learning – helping our clients better understand: where to play/how to play?
Oliver’s Team has been involved in some of the first Innovative Contracting Agreements (Outcomes-Based, Risk Share, Netflix Deals) across the Globe.